 |
|
|
| |
C-SCAPE: EFFICACY AND SAFETY OF 12 WEEKS OF GRAZOPREVIR ± ELBASVIR ± RIBAVIRIN IN PATIENTS WITH HCV GT2, 4, 5, OR 6 INFECTION
|
| |
| |
Reported by Jules Levin
EASL 2015 Vienna, Austria April 22-26
Ashley Brown1, Christophe Hezode2, Eli Zuckerman3, Graham Foster4, Amany Zekry5, Stuart Roberts6, Anita Howe7, Christine Durkan7, Cyrus Badshah7, Boan Zhang7, Michael Robertson7, Janice Wahl7, Eliav Barr7, Barbara Haber7
1Imperial College Healthcare NHS Trust, London, UK; 2Henri Mondor Hospital, University of Paris-Est, Creteil, France; 3Liver Unit, Carmel Medical Center Technion Faculty of Medicine, Haifa, Israel; 4Liver Unit, Queen Marys University of London, London UK; 5St George Hospital Clinical School, Inflammation and Infection Research Centre, University of New South Wales, Sydney, Australia; 6Alfred Hospital, Melbourne, Australia; 7Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
